GFAP and Alzheimer disease: Previous research has demonstrated that within the AD continuum, the plasma levels of GFAP, NfL, and p-tau181 exhibit a gradual increase, whereas the plasma Aβ1–42/Aβ1–40 ratio displays a progressive decline [14, 15].